3 results
Approved WMOCompleted
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
Approved WMOWill not start
Primary: Dose escalation part: To determine the MTD and/or RP2D of PDR001 in combination with regorafenib in patients with metastatic MSS CRC. Expansion part: To evaluate the efficacy based on overall response rate (ORR) of PDR001 in combination…
Approved WMORecruiting
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.